SCHEMBL89084

SCHEMBL89084

COCCCOc1cc(C)c(C)c(C(=O)NC2CC2)c1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.44
ALDH1A1 P00352 3/20 0.43
MEN1 O00255 2/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
CRHBP P24387 1/20 0.43
HTT P42858 1/20 0.43
CRHR2 Q13324 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
CNR1 P21554 6/20 0.42
CNR2 P34972 6/20 0.42
POLB P06746 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
EPHX2 P34913 1/20 0.40
MAPK14 Q16539 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1518112 0.82 MEN1 (0.41) KMT2AALDH1A1MEN1LMNAMAPT
SCHEMBL13163163 0.77 HPGDS (0.46) KMT2AALDH1A1MEN1LMNAMAPT
SCHEMBL2086693 0.76 MEN1 (0.66) KMT2AALDH1A1MEN1LMNACNR1
SCHEMBL90468 0.75 KMT2A (0.50) KMT2AALDH1A1MEN1CNR1CNR2
SCHEMBL89024 0.75 MEN1 (0.47) KMT2AALDH1A1MEN1CNR1CNR2
SCHEMBL89589 0.75 KDM4E (0.38) KMT2AALDH1A1MEN1HTTCNR1
SCHEMBL89655 0.75 MEN1 (0.68) KMT2AALDH1A1MEN1LMNACNR1
SCHEMBL1518477 0.73 KMT2A (0.57) KMT2AALDH1A1MEN1CNR1CNR2
SCHEMBL1518400 0.72 KMT2A (0.40) KMT2AALDH1A1MEN1LMNAMAPT
SCHEMBL1518397 0.72 KMT2A (0.40) KMT2AALDH1A1MEN1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
EP-2420491-A1 3 , 5-substitued piperidine compounds as renin inhibitors Novartis AG (CH) 2012-02-22 EP disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
WO-2007077005-A1 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS NOVARTIS AG (CH) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192148-A1 Organic Compounds REN, ACE, AGTR1 KMT2A 3129/4885ALDH1A1 38/4885MEN1 2336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.